## **Trustees’ Annual Report for the period** **From 1[st] January 2020 To 31[[st]] Charity name: Salivary Gland Cancer UK** ## **To 31[[st]] December 2020** ## **Charity registration number: 1182762** ## **Objectives and Activities** ||SORP reference|| |---|---|---| |Summary of the purposes of
the charity as set out in its
governing document|Para 1.17|Help those affected by rare salivary gland
cancers.
Advocate for these patients and carers by
providing peer support and information about
their disease, care and treatment.
Promote and assist research into all aspects
of salivary gland cancers, including causes,
diagnosis, treatment and cure.
To educate the public in all things related to
salivary gland cancers, including raising
awareness of symptoms.| |Summary of the main
activities in relation to those
purposes for the public
benefit, in particular, the
activities, projects or services
identified in the accounts.|Para 1.17 and
1.19|
Supporting the community via in person
and virtual meetings for patients, carers
and clinicians.

Providing information via leaflets,
meetings, the website and social media.

Raising awareness of these cancers and
their unmet need via speaking and
attending meetings and conferences.

Expansion of the network to support
more salivary gland cancer types.

Expansion of the charity’s outputs to
provide more research and disease
specific information, including pertinent
research updates.| |Statement confirming
whether the trustees have
had regard to the guidance
issued by the Charity
Commission on public
benefit|Para 1.18|The trustees have kept in mind the charity
Constitution and the guidance from the
Charities Commission in all of its’ activities.
The governance documents of the Charity
are regularly reviewed at Trustee meetings.| ## **Additional information (optional)** ## You may choose to include further statements where relevant about: SORP reference Para 1.38 Policy on grant making Para 1.38 Policy on social investment including program related investment Para 1.38 Contribution made by volunteers Other ## **Achievements and Performance** ||SORP reference|| |---|---|---| |Summary of the main
achievements of the charity,
identifying the difference the
charity’s work has made to
the circumstances of its
beneficiaries and any wider
benefits to society as a
whole.|Para 1.20|
_Supporting the community via in person_
_and virtual meetings for patients, carers_
_and clinicians._
For our in person meetings earlier in the
year we were able to support bursaries for
patients and their carers to support their in
person attendance when needed.
Adapting to a virtual environment by using
zoom for our meetings allowed us to
continue our support of the community
during lockdown.
We continued to provide regular
communication and newsletters to the
network.
Our October 2020 virtual meeting was
focussed on salivary gland cancers and your
mental health. This topic was identified as
an unmet need by our network.

_Providing information via leaflets,_
_meetings, the website and social media._
Leafletswere provided tonurses,hospitals| and other healthcare professionals. Ongoing development of the online presence and regular updates of social media and the website to highlight news and reports and key developments.  _Raising awareness of these cancers and their unmet need via speaking and attending meetings and conferences._ SGC UK had a poster at the ‘RareFest 2020’ festival organised by the University of Cambridge. The Chair presented at The Swallows ‘International Head and Neck Conference 2020’ on the importance of collaboration between patients, clinicians and healthcare providers.  _Expansion of the network to support more salivary gland cancer types._ Expansion of the network from Adenoid Cystic Carcinoma to other salivary gland cancers. We held specific events focussed on acinic cell carcinoma, ductal carcinoma and secretory carcinoma.  _Expansion of the charity’s outputs to provide more research and disease specific information, including research updates._ In March 2020 we held a researcher - clinician discussion day the outputs of which will not only feed into our strategy but inform our research priorities. We started a series of interviews with key researchers and clinicians involved in salivary gland cancer research. We started with a blog of an Interview with ACC Immunotherapy Researcher Dave Morgan. Our first podcast came from our August meeting where Dr Rob Metcalf talked about scans, in particular MRI and CT scans, and their role in discovering and monitoring disease in ACC. ## **Additional information (optional)** You may choose to include further statements where relevant about: |Achievements against
objectives set|Para 1.41|| |---|---|---| |Performance of fundraising
activities against objectives
set|Para 1.41|| |Investment performance
against objectives|Para 1.41|| |Other||| ## **Financial Review** |**Financial Review**||| |---|---|---| |Review of the charity’s
financial position at the end
of the period|Para 1.21|As at 31stDecember 2020 the charity held a
cash balance of £26,608, the result of
£9,531 in net receipts for the year. The
charity received income of £12,386 in
donations through various sources including
donation platforms and personal legacies.
The charity’s financial position will allow
sufficient funding to support the initiatives
planned for 2021.| |Statement explaining the
policy for holding reserves
stating why they are held|Para 1.22|The cash balance is held in order to support
the overall objectives of the charity. Cash is
used to cover operating expenses, develop
the charity’s presence through marketing
and fund specific patient/clinician events.
Due to the Covid-19 pandemic, no in-person
events were held during 2020 which
contributed to lower than expected expenses
being incurred.| |Amount of reserves held|Para 1.22|£26,608in cash.| |Reasons for holding zero
reserves|Para 1.22|Not applicable| |Details of fund materially in
deficit|Para 1.24|Not applicable| |Explanation of any
uncertainties about the
charity continuing as a going
concern|Para 1.23|There are no uncertainties around the
charity’s ability to continue as a going
concern.| |**Additional information (optional)**
You may choose to include further statements|**Additional information (optional)**
You may choose to include further statements|where relevant about:| |---|---|---| |The charity’s principal
sources of funds (including
any fundraising)|Para 1.47|| |Investment policy and
objectives including any
social investment policy
adopted|Para 1.46|| |A description of the principal
risks facing the charity|Para 1.46|| |Other||| ## **Structure, Governance and Management** |Description of charity’s
trusts:||| |---|---|---| |Type of governing document
(trust deed, royal charter)|Para 1.25|The charity is governed by its Constitution| |How is the charity
constituted?
(e.g unincorporated
association, CIO)|Para 1.25|The charity is a CIO| |Trustee selection methods
including details of any
constitutional provisions e.g.
election to post or name of
any person or body entitled
to appoint one or more
trustees|Para 1.25|Trustees must be appointed for a term of
three years by a resolution passed at a
properly convened meeting of the charity
trustees.
When selecting trustees, the charity trustees
have regard to the skills, knowledge and
experience needed for the effective
administration of the CIO.| **Additional information (optional)** You may choose to include further statements where relevant about: |Policies and procedures
adopted for the induction and
training of trustees|Para 1.51|| |---|---|---| |The charity’s organisational
structure and any wider
network with which the
charity works|Para 1.51|| |Relationship with any related
parties|Para 1.51|| |Other||| ## **Reference and Administrative details** Charity name Salivary Gland Cancer UK Other name the charity uses Registered charity number 1182762 Charity’s principal address International House, 24 Holborn Viaduct, London EC1A 2BN **Names of the charity trustees who manage the charity** |1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20|**Trustee name**|**Office (if any)**|**Dates acted if not for whole**
**year**|**Name of person (or body) entitled**
**to appoint trustee(if any)**| |---|---|---|---|---| ||Emma Jane
Kinloch|Chair||The Board| ||Dr Robert Metcalf|Trustee||The Board| ||Olorunkemi Fausat
Akanke Olaiya|Treasurer||The Board| ||Shane Lisa Draper|Chief Financial
Officer||The Board| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| Corporate trustees – names of the directors at the date the report was approved **Director name** Name of trustees holding title to property belonging to the charity **Trustee name Dates acted if not for whole year** ## **Funds held as custodian trustees on behalf of others** Description of the assets Not applicable held in this capacity Name and objects of the Not applicable charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for Not applicable safe custody and segregation of such assets from the charity’s own assets ## **Additional information (optional)** ## **Names and addresses of advisers (Optional information)** **Type of Name Address adviser** **Name of chief executive or names of senior staff members (Optional information)** ## **Exemptions from disclosure** Reason for non-disclosure of key personnel details ## **Other optional information** |
**Salivary Gland Cancer UK**
|
**Salivary Gland Cancer UK**
|
**Salivary Gland Cancer UK**
|**No (if any)**
**1182762**|**CC16a**| |---|---|---|---|---| |**Receipts andpayments accounts**||||| |**For the period**
**from**|Period start date|**To**|Period end date
**31st December 2020**|| ||**1st January 2020**|||| |**Section A Receipts and payments**|**Section A Receipts and payments**||||| |---|---|---|---|---|---| |**A1 Receipts**|**Unrestricted**
**funds**
**to the nearest £**
**12,000**
**264**
**123**
**-**
**-**
**-**
**-**
**-**

**12,386**
**-**
**-**
**-**
**12,386**
**2,607**
**218**
**30**
**-**
**-**
**-**
**-**
**-**
**-**
**2,855**
**-**
**-**
**-**
**2,855**
**9,531**
**-**
**17,077**
**26,608**|**Restricted**
**funds**
**to the nearest £**|**Endowment**
**funds**
**to the nearest £**|**Total funds**
**to the nearest £**|**Last year**
**to the nearest £**| |Donations via Just Giving, Easy
Fundraising, Amazon, Paypal|**12,000**|**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**-**|**12,000**|**-**| |Donations received from
organisations/individuals|**264**||**-**|**264**|**-**| |Foreign income(USD)|**123**||**-**|**123**|**-**| ||**-**||**-**|**-**|**-**| ||**-**||**-**|**-**|**-**| ||**-**||**-**|**-**|**-**| ||**-**||**-**|**-**|**-**| ||**-**||**-**
**-**|**-**
**12,386**|**-**| |**_Sub total_**_(Gross income for_
_AR)_|
**12,386**||||**-**| ||||||| |**A2 Asset and investment sales,**
**(see table).**|||||| ||**-**|**-**
**-**
**-**|**-**|**-**|| ||**-**||**-**
**-**|**-**
**-**|**-**| |**_Sub total_**|**-**||||**-**| |**_Total receipts_**
**A3 Payments**|||||| |||**-**|**-**|**12,386**|**-**| ||||||| |
Charity admin expenses and running costs|**2,607**|**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**-**|**2,607**|**-**| |In person meeting expenses e.g. room hire|**218**||**-**|**218**|**-**| |Bursaries for attendees|**30**||**-**|**30**|**-**| |Memberships and collaborative expenses|**-**||**-**|**-**|**-**| |Entry into events for members fundraising|**-**||**-**|**-**|**-**| ||**-**||**-**|**-**|**-**| ||**-**||**-**|**-**|**-**| ||**-**||**-**|**-**|**-**| ||**-**||**-**
**-**|**-**
**2,855**|**-**| |**_Sub total_ **|**2,855**||||**-**| ||||||| |**A4 Asset and investment**
**purchases, (see table)**|||||| ||**-**|**-**
**-**
**-**|**-**|**-**|| ||**-**||**-**
**-**|**-**
**-**|| |**_Sub total_ **|**-**||||**-**| |**_Total payments_**
**_Net of receipts/(payments)_**
**A5 Transfers between funds**
**A6 Cash funds last year end**
**_Cash funds this year end_**||||**2,855**|| |||**-**|**-**||**-**| ||||||| ||**9,531**|**-**|
**-**|**9,531**|**-**| ||**-**|**-**
**-**|**-**|**-**|**-**| ||**17,077**||**-**|**17,077**|**-**| ||**26,608**|**-**|
**-**|**26,608**|**-**| ## **Section B Statement of assets and liabilities at the end of the period** |**Categories**
**B1 Cash funds**|**Details**
Bank account balance (Lloyds)
Paypal account balance|**Unrestricted**
**funds**
**to nearest £**|**Restricted funds**
**to nearest £**|**Endowment**
**funds**
**to nearest £**| |---|---|---|---|---| |||**23,869**|**-**|**-**| |||**2,739**|**-**|**-**| |||**-**|**-**|**-**| |Signed by one or two trustees on
behalf of all the trustees
**B2 Other monetary assets**
**B3 Investment assets**
**B4 Assets retained for the**
**charity’s own use**
**B5 Liabilities**|(agree balances with receipts and payments
account(s))
**_Total cash funds_**
**Details**
**Details**
**Details**
**Details**
Signature|**26,608**
**-**
OK
OK
**Unrestricted**
**funds**
**Restricted funds**
**to nearest £**
**to nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**asset belongs**
**Cost (optional)**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**asset belongs**
**Cost (optional)**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**liability relates**
**Amount due (optional)**
**-**
**-**
**-**
**-**
**-**
Print Name
Kemi Olaiya
Shane Draper|**-**|**-**| |---|---|---|---|---| |||||OK| |||||**Endowment**
**funds**
**to nearest £**| |||||**-**| |||||**-**| |||||**-**| |||||**-**| |||||**-**| |||||**-**| |||||**Current value**
**(optional)**| |||||**-**| |||||**-**| |||||**-**| |||||**-**| |||||**-**| |||||**Current value**
**(optional)**| |||||**-**| |||||**-**| |||||**-**| |||||**-**| |||||**-**| |||||**-**| |||||**-**| |||||**-**| |||||**-**| |||||**When due**
**(optional)**| |||||| |||||| |||||| |||||| |||||| |||||| |||||Date of
approval| |||||**26-Oct-21**| |||||**26-Oct-21**|